Cardiovascular disease prevention, blood pressure, cholesterol, and heart function
617 articoli
A formal correction is issued to the landmark 2025 multi-society hypertension guidelines, ensuring clinical accuracy for practitioners.
A correction to a landmark study linking breast cancer to latent BMPR2-driven pulmonary hypertension susceptibility in Circulation.
A landmark 8,500-patient trial challenges 40 years of cardiology practice, finding beta blockers unnecessary after uncomplicated heart attacks.
A landmark Phase 3 trial evaluates whether omecamtiv mecarbil, a cardiac myosin activator, reduces cardiovascular death in HFrEF patients.
A phase 3 trial adding ERN/LRPT to statin therapy for dyslipidemia was terminated early, raising questions about the drug's clinical future.
A newly discovered protein called HELZ2 controls how much harmful cholesterol the liver releases, opening a fresh path to heart disease treatment.
Scientists uncover how faulty glycogen-priming proteins cause progressive cardiomyopathy, pointing toward gene therapy and autophagy as future treatments.
A Phase 1 trial examines if the triple-agonist GLP-1 drug retatrutide changes how the body processes the beta-blocker metoprolol.
A new NEJM perspective examines hypertension's central role in cardiovascular risk, with implications for prevention and clinical management.
A landmark Lancet registry finds coronary microvascular dysfunction raises major cardiac event risk by 91%, even after treating visible blockages.
A Lancet review spotlights how small vessel dysfunction silently worsens atherosclerotic coronary disease, reshaping diagnosis and treatment.
A feedforward ANGPT-TIE2 signaling loop amplifies PIK3CA-driven venous malformations, pointing to TIE2 inhibition as a more effective therapy than mTOR blockade.
